Identification of MPL W515L/K mutations in patients with primary myelofibrosis and essential thrombocythaemia by allele-specific polymerase chain reaction

Acta Haematologica

Volumn 121, Issue 4, 2009, Pages 221-222

  Daly, Sarah ^a   Conneally, Eibhlin ^a   Langabeer, Stephen E ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ALLELE; ARTICLE; GENE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MPL GENE; MYELOID METAPLASIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTHEMIA;

ALLELES; DNA MUTATIONAL ANALYSIS; HUMANS; JANUS KINASE 2; MUTATION, MISSENSE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIMARY MYELOFIBROSIS; RECEPTORS, THROMBOPOIETIN; RETROSPECTIVE STUDIES; THROMBOCYTHEMIA, ESSENTIAL;

EID: 66749118350     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000224333     Document Type: Article

References (8)

1. Levine RL, Pardanani A, Tefferi A, Gilliland DG: Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007; 7: 673-683. (Pubitemid 47327415)
2. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL: MPL W515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270. (Pubitemid 44125998)
3. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, Mc-Clure RF, Litzow MR, Gilliland DG, Tefferi A: MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472-3476. (Pubitemid 44776889)
4. Guglielmelli P, Pancrazzi A, Bergamaschi G, Rosti V, Antonioli E, Bosi A, Barosi G, Vannucchi AM: Anaemia characterises patients with myelofibrosis harbouring MPL mutation. Br J Haematol 2007; 137: 244-247. (Pubitemid 46537640)
5. Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, Wilkins BS, Reilly JT, Hasselblach HC, Bowman R, Wheatley K, Buck G, Harrison CN, Green AR: MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008; 112: 141-149.
6. Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G, Ruggeri M, Specchia G, Lo-Coco F, Delaini F, Villani L, Finotto S, Ammatuna E, Alterini R, Carrai V, Capaccioli G, Di Lollo S, Liso V, Rambaldi A, Bosi A, Barbui T: Characteristics and clinical correlates of MPL 515W > L/K in essential thrombocythaemia. Blood 2008; 112: 844-847.
7. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou G, Bench AJ, Boyd EM, Erber WN, Green AR & Cancer Genome Project: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061. (Pubitemid 40386783)
8. Pardanini A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, Finke C, Mak CC, Mesa R, Zhu H, Soll R, Gilliland DG, Tefferi A: TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2 V617F and MPL W515L/K mutations. Leukemia 2007; 21: 1658-1668. (Pubitemid 47086756)